Health · Public Health & Disease · 2 hrs ago
Tamil Nadu begins India's first dengue vaccine study in Tenkasi
Tamil Nadu is conducting India's first dengue vaccine study in Tenkasi district, Health Minister K G Arunraj said.
The study is overseen by the Indian Council of Medical Research and will assess how the vaccine works in Indian conditions.
The vaccine is already part of Brazil's immunisation schedule, Arunraj said.
He said it currently offers 80 to 90 per cent protection against severe illness and hospitalisation.
The state says dengue is under control now, but the minister warned that the rainy season over the next two to three months could bring greater challenges.
He urged residents to prevent water from collecting around their homes and to seek hospital care for fever rather than self-medicate.
Tamil Nadu is conducting India’s first dengue vaccine study in Tenkasi district, Health Minister K G Arunraj said.
The study is overseen by the Indian Council of Medical Research.
The vaccine is being evaluated for its effectiveness in Indian conditions.
Arunraj said it currently offers 80 to 90 per cent protection against severe consequences and hospitalisation.
He said dengue is under control, but the rainy season over the next two to three months will be a challenge.
- Who
- Tamil Nadu is conducting the study, overseen by the Indian Council of Medical Research.
- What
- India’s first dengue vaccine study is evaluating the vaccine’s effectiveness in Indian conditions.
- When
- The study was under way as of October 22, 2026.
- Where
- Tenkasi district, Tamil Nadu, India.
- Why
- To evaluate the vaccine’s effectiveness in Indian conditions.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Study location
- Tenkasi district, Tamil Nadu
- Oversight
- Indian Council of Medical Research
- Reported protection
- 80 to 90 per cent against severe consequences and hospitalisation
- Minister
- K G Arunraj
What people are saying
It is being evaluated for its effectiveness in Indian conditions and currently offers 80 to 90 per cent protection against severe consequences and hospitalisation